Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases
Shots:
- The P-II (ALPACA) trial assessed lepodisiran (16, 96, or 400mg) vs PBO for ~18mos. in 320 pts, who were dosed at baseline & day 180, with an additional arm receiving 400mg at baseline & PBO at day 180; P-III [ACCLAIM-Lp(a)] trial enrollment is ongoing
- Trial met its 1EP, with 400mg reducing Lp(a) by 93.9% over 60-180 days; 16 mg & 96 mg showed 40.8% & 75.2% reductions, respectively; impact of additional lepodisiran doses remain unknown
- 2EPs showed 400mg (dosed twice) reduced Lp(a) by 94.8% (day 30-360), sustained at 91% at ~1yr. & 74.2% at ~1.5yrs., with ApoB reductions of 14.1% (day 60) & 13.7% (day 180), maintained through day 540; data was presented at ACC 2025 & published in The NEJM
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
